Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment

Cathy Eng, MD
Published: Thursday, Nov 09, 2017



Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

The question of choosing between regorafenib and TAS-102 is one that comes up frequently in clinical practice, Eng explains. Regorafenib may be associated with increased liver function tests; therefore, for a patient with significant tumor burden in the live, this agent may not be the primary treatment choice. Additionally, regorafenib is an angiogeneic agent, so if physicians are concerned about patients' blood pressure, risk of stroke, or potential risk of bowel obstruction, TAS-102 may be a more appropriate choice.

However, TAS-102 results in increased myelosuppression. In this case, physicians can adjust a patients' dosing schedule or pegfilgrastim (Neulasta). Both regorafenib and TAS-102 are oral agents and require close follow-up of agents, Eng adds. 

    <<< View more from the 2017 Chemotherapy Foundation Symposium


Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

The question of choosing between regorafenib and TAS-102 is one that comes up frequently in clinical practice, Eng explains. Regorafenib may be associated with increased liver function tests; therefore, for a patient with significant tumor burden in the live, this agent may not be the primary treatment choice. Additionally, regorafenib is an angiogeneic agent, so if physicians are concerned about patients' blood pressure, risk of stroke, or potential risk of bowel obstruction, TAS-102 may be a more appropriate choice.

However, TAS-102 results in increased myelosuppression. In this case, physicians can adjust a patients' dosing schedule or pegfilgrastim (Neulasta). Both regorafenib and TAS-102 are oral agents and require close follow-up of agents, Eng adds. 

    <<< View more from the 2017 Chemotherapy Foundation Symposium



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x